



Mylan Joins HarborPath to Help Uninsured Individuals with HIV/AIDS Access Prescription Medicines

-Participating supporters include AbbVie, Johnson & Johnson Patient Assistance Foundation, Inc. Merck and ViiV Healthcare –

Charlotte, NC – May 22, 2019, HarborPath, an organization dedicated to assisting patients gain access to their entire regimen of HIV/AIDS medications through patient assistance programs, welcomes Mylan as a participating company in support of the HarborPath Portal. As our newest participant, Mylan will donate several HIV-1 prescription drugs, which will further strengthen HarborPath’s portfolio of HIV/AIDS medications available to eligible uninsured patients. Mylan is the most recent company to donate medications to HarborPath since its formation in July 2012.

HarborPath provides a single point of access for a vulnerable patient population and is a national medication access program working with clinics and healthcare providers throughout the U.S. to help provide free medications to uninsured, indigent patients. “With Mylan’s product donation, HarborPath can further assist patients in meeting a critical need and greatly increasing medication adherence,” said Ken Trogdon, Jr., President of HarborPath.

“As a global leader in the fight against HIV/AIDS, we appreciate the urgent need for newly diagnosed individuals to initiate and stay on therapy and are pleased to help HarborPath to provide free HIV medications to support eligible, uninsured patients access immediate care at a critical point in their journey,” said Anil Soni, Mylan’s head of Global Infectious Disease.

###

About HarborPath

HarborPath is a 501 (c)(3) organization whose mission is to provide streamlined access to HIV/AIDS medications through patient assistance programs via an online portal. For more information, visit www.harborpath.org.

About Mylan

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which more than 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at www.Mylan.com. Mylan routinely posts information that may be important to investors at investor.mylan.com

Media Contacts:

Ken Trogdon Jr.
President
HarborPath
980-859-3483
Ken.trogdon@harborpath.org